Linked Life Data

16861623

Source:http://linkedlifedata.com/resource/pubmed/id/16861623

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16861623rdf:typepubmed:Citationlld:pubmed
pubmed-article:16861623lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:16861623lifeskim:mentionsumls-concept:C0025663lld:lifeskim
pubmed-article:16861623lifeskim:mentionsumls-concept:C0032105lld:lifeskim
pubmed-article:16861623lifeskim:mentionsumls-concept:C1706515lld:lifeskim
pubmed-article:16861623lifeskim:mentionsumls-concept:C0025879lld:lifeskim
pubmed-article:16861623lifeskim:mentionsumls-concept:C1704640lld:lifeskim
pubmed-article:16861623lifeskim:mentionsumls-concept:C0680730lld:lifeskim
pubmed-article:16861623lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:16861623lifeskim:mentionsumls-concept:C1519941lld:lifeskim
pubmed-article:16861623lifeskim:mentionsumls-concept:C1148554lld:lifeskim
pubmed-article:16861623lifeskim:mentionsumls-concept:C0331858lld:lifeskim
pubmed-article:16861623pubmed:issue10lld:pubmed
pubmed-article:16861623pubmed:dateCreated2006-9-29lld:pubmed
pubmed-article:16861623pubmed:abstractTextA simple, specific, and sufficiently sensitive liquid chromatography-tandem mass spectrometry (negative-ion electrospray ionization) methodology to determine mevalonic acid (MVA) in human plasma is described, and its application to the analysis of rat plasma MVA levels after rosuvastatin administration is demonstrated. The method was validated over the linearity range of 0.5-50.0 ng/ml (r(2) > 0.99) using deuterated MVA as an internal standard. The lower limit of quantification was 0.5 ng/ml. The assay procedure involved the isolation of MVA from plasma samples using solid-phase extraction. Chromatographic separation was achieved on a HyPurity Advance column with a mobile phase consisting of ammonium formate buffer (10 mM, pH 8.0) and acetonitrile (70:30, v/v). Excellent precision and accuracy were observed. MVA and deuterated mevalonolactone were stable in water and plasma under different storage and processing conditions. The recovery observed was low, which was attributable to a significant matrix effect. A significant decrease (30-40%; P < 0.05) was observed in rat plasma MVA levels after rosuvastatin administration.lld:pubmed
pubmed-article:16861623pubmed:languageenglld:pubmed
pubmed-article:16861623pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16861623pubmed:citationSubsetIMlld:pubmed
pubmed-article:16861623pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16861623pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16861623pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16861623pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16861623pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16861623pubmed:statusMEDLINElld:pubmed
pubmed-article:16861623pubmed:monthOctlld:pubmed
pubmed-article:16861623pubmed:issn0022-2275lld:pubmed
pubmed-article:16861623pubmed:authorpubmed-author:GautamAAlld:pubmed
pubmed-article:16861623pubmed:authorpubmed-author:AhmedTTlld:pubmed
pubmed-article:16861623pubmed:authorpubmed-author:RajanK SKSlld:pubmed
pubmed-article:16861623pubmed:authorpubmed-author:PillaiK KKKlld:pubmed
pubmed-article:16861623pubmed:authorpubmed-author:PaliwalJ KJKlld:pubmed
pubmed-article:16861623pubmed:authorpubmed-author:SainiG SGSlld:pubmed
pubmed-article:16861623pubmed:authorpubmed-author:VarshneyBBlld:pubmed
pubmed-article:16861623pubmed:authorpubmed-author:WaniT ATAlld:pubmed
pubmed-article:16861623pubmed:issnTypePrintlld:pubmed
pubmed-article:16861623pubmed:volume47lld:pubmed
pubmed-article:16861623pubmed:ownerNLMlld:pubmed
pubmed-article:16861623pubmed:authorsCompleteYlld:pubmed
pubmed-article:16861623pubmed:pagination2340-5lld:pubmed
pubmed-article:16861623pubmed:meshHeadingpubmed-meshheading:16861623...lld:pubmed
pubmed-article:16861623pubmed:meshHeadingpubmed-meshheading:16861623...lld:pubmed
pubmed-article:16861623pubmed:meshHeadingpubmed-meshheading:16861623...lld:pubmed
pubmed-article:16861623pubmed:meshHeadingpubmed-meshheading:16861623...lld:pubmed
pubmed-article:16861623pubmed:meshHeadingpubmed-meshheading:16861623...lld:pubmed
pubmed-article:16861623pubmed:meshHeadingpubmed-meshheading:16861623...lld:pubmed
pubmed-article:16861623pubmed:meshHeadingpubmed-meshheading:16861623...lld:pubmed
pubmed-article:16861623pubmed:meshHeadingpubmed-meshheading:16861623...lld:pubmed
pubmed-article:16861623pubmed:meshHeadingpubmed-meshheading:16861623...lld:pubmed
pubmed-article:16861623pubmed:meshHeadingpubmed-meshheading:16861623...lld:pubmed
pubmed-article:16861623pubmed:meshHeadingpubmed-meshheading:16861623...lld:pubmed
pubmed-article:16861623pubmed:meshHeadingpubmed-meshheading:16861623...lld:pubmed
pubmed-article:16861623pubmed:meshHeadingpubmed-meshheading:16861623...lld:pubmed
pubmed-article:16861623pubmed:meshHeadingpubmed-meshheading:16861623...lld:pubmed
pubmed-article:16861623pubmed:meshHeadingpubmed-meshheading:16861623...lld:pubmed
pubmed-article:16861623pubmed:year2006lld:pubmed
pubmed-article:16861623pubmed:articleTitleValidation of the LC-MS/MS method for the quantification of mevalonic acid in human plasma and determination of the matrix effect.lld:pubmed
pubmed-article:16861623pubmed:affiliationDepartment of Metabolism and Pharmacokinetics, Ranbaxy Research Laboratories, Jamia Hamdard, Delhi, India.lld:pubmed
pubmed-article:16861623pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16861623pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16861623lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16861623lld:pubmed